UT Texas Natalizumab treated and Untreated MS Patients.

1Age assessed at time of enrollment in this study.
2EDSS assessed at time of enrollment in this study.
3N/A  =  Not applicable. Patient started natalizumab after initial approval by the Food and Drug Administration.
4AFFIRM  =  Natalizumab safety and efficacy in relapsing remitting multiple sclerosis.
5SENTINEL  =  The safety and efficacy of natalizumab in combination with interferon beta-1a in patients with relapsing-remitting multiple sclerosis RRMS  =  relapsing-remitting multiple sclerosis; PPMS  =  primary progressive multiple sclerosis; SPMS  =  secondary progressive multiple sclerosis; CIS-ON  =  clinically isolated syndrome/optic neuritis; ND  =  not determined.